Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute

Drug Profile

Research programme: tuberculosis therapies - ChemDiv/Chemical Diversity Research Institute

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator ChemDiv; Chemical Diversity Research Institute; Novartis Institute for Tropical Diseases
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 06 Oct 2011 Chemical Diversity Research Institute enters collaboration and License Option Agreement with Novartis Institute for Tropical Diseases for this research programme
  • 06 Oct 2011 Preclinical trials in Tuberculosis in Singapore (unspecified route)
  • 15 Apr 2009 Preclinical development is ongoing in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top